Key facts
- MindImmune’s last known valuation is $43.5M (Nov 2025).
- It has raised $30.3M; the latest was Grant ($5.0M) in Mar 2026.
- Notable investors include Dolby Family Ventures, Pfizer Ventures, Gates Frontier, Alzheimers Drug Discovery Foundation, Foundation For a Better World — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for MindImmune
- ·The full record, as it builds
Funding rounds
No funding rounds for MindImmune are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MindImmune
Developer of antibody-based drugs and therapeutics designed to treat diseases of the central nervous system. The company specializes in helping to recognize the therapeutic enhancements in targeting the immune system by focusing on neuroinflammation to treat brain diseases, Alzheimer's, Huntington's disease and psychiatric disorders, enabling neuroscientists to treat their patients by inhibiting an innate immune response originating in the periphery.
- Sector
- Healthcare
- HQ
- Kingston, RI, United States
- Founded
- 2016
- Employees
- 10
- Website
- mindimmune.com/
- Ownership
- Privately Held (backing)
MindImmune doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MindImmune shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MindImmune in its N-PORT filings yet. We sweep new filings monthly.